DIMENSIONAL FUND ADVISORS LP - ALPINE IMMUNE SCIENCES INC ownership

ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 36 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
DIMENSIONAL FUND ADVISORS LP ownership history of ALPINE IMMUNE SCIENCES INC
ValueSharesWeighting
Q3 2023$1,915,501
+31.7%
167,308
+18.2%
0.00%
Q2 2023$1,454,631
+34.9%
141,499
+1.3%
0.00%
Q1 2023$1,078,021
+148592.6%
139,672
+41.4%
0.00%
Q4 2022$725
-99.8%
98,807
+92.3%
0.00%
Q3 2022$370,000
-15.3%
51,3700.0%0.00%
Q2 2022$437,000
-8.2%
51,370
-3.2%
0.00%
Q1 2022$476,000
-35.2%
53,0640.0%0.00%
Q4 2021$735,000
+36.6%
53,064
+5.4%
0.00%
Q3 2021$538,000
+31.9%
50,364
+11.2%
0.00%
Q2 2021$408,000
-15.0%
45,3000.0%0.00%
Q1 2021$480,000
-20.9%
45,300
-5.9%
0.00%
Q4 2020$607,000
+43.5%
48,1540.0%0.00%
Q3 2020$423,000
+7.4%
48,154
+18.7%
0.00%
Q2 2020$394,000
+198.5%
40,554
-11.8%
0.00%
Q1 2020$132,000
-25.4%
45,9970.0%0.00%
Q4 2019$177,000
-1.7%
45,9970.0%0.00%
Q3 2019$180,000
-1.6%
45,997
+5.7%
0.00%
Q2 2019$183,000
-36.0%
43,512
+4.4%
0.00%
Q1 2019$286,000
+104.3%
41,667
+9.4%
0.00%
Q4 2018$140,000
-41.9%
38,0890.0%0.00%
Q3 2018$241,000
-2.8%
38,089
+16.1%
0.00%
Q2 2018$248,000
+110.2%
32,819
+122.2%
0.00%
Q1 2018$118,000
-28.5%
14,7670.0%0.00%
Q4 2017$165,000
-3.5%
14,7670.0%0.00%
Q3 2017$171,00014,7670.00%
Other shareholders
ALPINE IMMUNE SCIENCES INC shareholders Q3 2020
NameSharesValueWeighting ↓
FRAZIER MANAGEMENT LLC 2,571,450$23,143,0002.13%
Omega Fund Management, LLC 1,284,900$11,564,0001.31%
Avidity Partners Management LP 1,495,000$13,455,0000.36%
Samsara BioCapital, LLC 275,169$2,477,0000.31%
Orbimed Advisors 3,070,955$27,639,0000.28%
Ikarian Capital, LLC 300,454$2,704,0000.22%
TIGER MANAGEMENT L.L.C. 137,728$1,240,0000.22%
DAFNA Capital Management LLC 113,302$1,020,0000.21%
EcoR1 Capital, LLC 522,635$4,704,0000.18%
Artal Group S.A. 593,030$5,337,0000.11%
View complete list of ALPINE IMMUNE SCIENCES INC shareholders